SRC and breast cancer: To develop novel treatment strategies against triple negative/basal-like breast cancer, molecular targeting agents such as inhibitors of Src, poly(ADP-ribose) polymerase (PARP) 1, HER1 or the vascular endothelial growth factor (VEGF) signaling pathway have been tested in preclinical and clinical studies [4].